Vicarious Surgical, Inc. Class A (RBOT)

Vicarious Surgical, Inc.'s stock price has declined significantly, falling 83.80% from February 4, 2025, to February 3, 2026, and has exhibited volatility. The company reported Q3 2025 EPS of -$1.91, exceeding expectations. They reduced their full-year 2025 cash burn outlook to approximately $45 million. A strategic software execution partnership was announced to streamline operations and cut development costs. Insiders engaged in multiple sell transactions of Class A Common Stock. The NYSE announced it would delist Vicarious Surgical's warrants. The company advanced toward design freeze with a successful in-vivo porcine lab study. Vicarious Surgical Inc. filed a $100M mixed shelf offering.

There is no specific information available regarding the demand seasonality for Vicarious Surgical, Inc.'s products and services.

Vicarious Surgical, Inc. (RBOT), founded in 2014 and based in Waltham, Massachusetts, is a robotics technology company focused on improving surgical procedure costs, efficiency, and patient outcomes. Their primary product, the Vicarious Surgical System, is a single-port surgical robot designed for minimally invasive surgery with 3D visualization and precise control, initially targeting hernia repairs. The system has received FDA Breakthrough Device Designation.

Vicarious Surgical, Inc. is headquartered in Waltham, Massachusetts, and has expanded its facilities there to increase capacity for development, testing, and manufacturing, including operating rooms for demonstration and testing. The company develops and sells its single-port surgical robot in the United States.

Vicarious Surgical's brand reputation is supported by its innovative technology and the FDA Breakthrough Device Designation. However, the company's stock performance and the NYSE's decision to delist its warrants could negatively impact its financial reputation and investor confidence. The company continues to advance its technology through successful studies and strategic partnerships.

Vicarious Surgical Inc. has 48 institutional owners and shareholders holding a total of 1,489,775 shares, including Vk Services, Llc, Vanguard Group Inc, and BlackRock, Inc. Individual owners include co-founders Adam Sachs and Sammy Khalifa, who have engaged in stock sales. The company is also backed by technology luminaries such as Bill Gates and Vinod Khosla's Khosla Ventures.